Why the study?
Do ABCB1 and CYP2C19 polymorphisms increase the risk of restenosis or occlusion in peripheral artery disease patients treated with clopidogrel following percutaneous transluminal angioplasty?
Do ABCB1 and CYP2C19 polymorphisms increase the risk of restenosis or occlusion in peripheral artery disease patients treated with clopidogrel following percutaneous transluminal angioplasty?
CYP2C19 and ABCB1 polymorphisms are associated with a significantly higher risk of restenosis, occlusion, and ischemic events in peripheral artery disease patients treated with clopidogrel after percutaneous transluminal angioplasty.
Supports caution with clopidogrel in variant PAD patients; leaves open whether genotyping improves outcomes.
AIM: To study the association of ABCB1 and CYP2C19 polymorphisms and the clopidogrel response in Spanish peripheral artery disease patients following percutaneous transluminal angioplasty (PTA) and to perform a meta-analysis. MATERIALS & METHODS: 72 patients were recruited and 122 patients included in the meta-analysis. We evaluated the effect of ABCB1 3435 C>T, CYP2C19*2 and CYP2C19*3 and primary end point (restenosis/occlusion of the treated lesions) during 12 months after PTA. RESULTS: CYP2C19*2 and/or ABCB1 TT patients were associated with primary end point (OR: 5.00; 95% CI: 1.75-14.27). The meta-analysis confirmed the association of CYP2C19*2 and new atherothrombotic ischemic events (OR: 5.40; 95% CI: 2.30-12.70). CONCLUSION: The CYP2C19 and ABCB1 polymorphisms could be genetic markers of cardiovascular events in peripheral artery disease patients following PTA treated with clopidogrel.
No takes yet. Share an insight, caveat, or question.
Díaz-Villamarín et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: